Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Liberty Media Series A
FWONA
$23.7B
| $13.6M | 0.01% |
397,133
+117,712
| +42% | +$4.11M |
|
|
CCXI
1202
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.6M | 0.01% |
1,465,381
+332,127
| +29% | +$3.84M |
|
1203
Herc Holdings
HRI
$5.63B
| $13.6M | 0.01% |
296,600
+135,800
| +84% | +$5.66M |
|
1204
Vera Bradley
VRA
$96.7M
| $13.6M | 0.01% |
1,132,300
-167,700
| -13% | -$1.99M |
|
1205
iShares US Real Estate ETF
IYR
$4.52B
| $13.6M | 0.01% |
155,600
+135,000
| +655% | +$11.8M |
|
1206
uniQure
QURE
$3.13B
| $13.6M | 0.01% |
173,700
+99,300
| +133% | +$6.33M |
|
1207
Zai Lab
ZLAB
$2.86B
| $13.5M | 0.01% |
388,531
+220,731
| +132% | +$6.5M |
|
1208
Radian Group
RDN
$4.87B
| $13.5M | 0.01% |
592,200
-111,500
| -16% | -$2.54M |
|
|
LTM
1209
DELISTED
LATAM Airlines Group S.A American Depositary Shares (Each representing 1 Common Share)
LTM
| $13.5M | 0.01% |
1,443,090
+78,500
| +6% | +$754K |
|
1210
Cintas
CTAS
$81.4B
| $13.5M | 0.01% |
+227,472
| New | +$12.6M |
|
1211
Cullen/Frost Bankers
CFR
$10.4B
| $13.5M | 0.01% |
144,000
-31,400
| -18% | -$3.07M |
|
|
CUTR
1212
DELISTED
Cutera, Inc.
CUTR
| $13.5M | 0.01% |
648,600
+44,600
| +7% | +$797K |
|
|
PLAN
1213
DELISTED
Anaplan, Inc.
PLAN
| $13.5M | 0.01% |
+266,900
| New | +$11M |
|
1214
British American Tobacco
BTI
$120B
| $13.4M | 0.01% |
385,334
+196,100
| +104% | +$7.43M |
|
1215
VEON
VEON
$3.92B
| $13.3M | 0.01% |
190,615
+157,631
| +478% | +$9.42M |
|
1216
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
$17.1B
| $13.3M | 0.01% |
130,500
+31,000
| +31% | +$3.15M |
|
|
ACB
1217
Aurora Cannabis
ACB
$237M
| $13.3M | 0.01% |
14,116
+7,544
| +115% | +$7.58M |
|
|
ODP
1218
DELISTED
ODP
ODP
| $13.3M | 0.01% |
643,407
+44,338
| +7% | +$1M |
|
|
EFOR
1219
Everforth Inc
EFOR
$1.34B
| $13.2M | 0.01% |
218,394
+1,000
| +0.5% | +$60.1K |
|
|
NGD
1220
DELISTED
New Gold Inc
NGD
| $13.2M | 0.01% |
13,764,730
+4,249,390
| +45% | +$3.38M |
|
1221
Central Garden & Pet Co
CENT
$2.79B
| $13.2M | 0.01% |
613,125
-155,500
| -20% | -$3.43M |
|
1222
Oil-Dri
ODC
$1.28B
| $13.2M | 0.01% |
776,408
+4,200
| +0.5% | +$65.5K |
|
1223
Nutanix
NTNX
$17.5B
| $13.2M | 0.01% |
508,696
-166,530
| -25% | -$5.8M |
|
|
FFIC
1224
DELISTED
Flushing Financial
FFIC
| $13.2M | 0.01% |
593,860
+25,200
| +4% | +$556K |
|
1225
Glaukos
GKOS
$11B
| $13.2M | 0.01% |
174,400
+86,405
| +98% | +$6.2M |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.